Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanzalintinib + Paclitaxel in Recurrent High Grade Uterine Cancer
NCT06795009Phase 1Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2025
- Primary completion
- Nov 2029
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of zanzalintinib in uterine cancer and endometrial cancer (EC) (3 arms), sponsored by Washington University School of Medicine. Primary endpoint: Recommended Phase 2 dose at 21 days. Started Oct 2025; status: recruiting.
02
Drugs
zanzalintinib
03
Conditions
uterine cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT06795009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06795009.